These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection. Okuda K, Kaneko T, Yamakawa T, Tanaka S, Shigematsu T, Yamamoto A, Hamajima K, Nakajima K, Kawamoto S, Phanuphak P. J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667 [Abstract] [Full Text] [Related]
9. Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model. Notka F, Stahl-Hennig C, Dittmer U, Wolf H, Wagner R. Biol Chem; 1999 Mar; 380(3):341-52. PubMed ID: 10223337 [Abstract] [Full Text] [Related]
10. Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. Luo L, Li Y, Cannon PM, Kim S, Kang CY. Proc Natl Acad Sci U S A; 1992 Nov 01; 89(21):10527-31. PubMed ID: 1438241 [Abstract] [Full Text] [Related]
11. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. McBurney SP, Young KR, Ross TM. Virology; 2007 Feb 20; 358(2):334-46. PubMed ID: 17011011 [Abstract] [Full Text] [Related]
12. Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles. Halsey RJ, Tanzer FL, Meyers A, Pillay S, Lynch A, Shephard E, Williamson AL, Rybicki EP. Virus Res; 2008 May 20; 133(2):259-68. PubMed ID: 18329748 [Abstract] [Full Text] [Related]
13. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1. Borbe HC, Stuber G, Wagner R, Wolf H, Modrow S. J Pept Sci; 1995 May 20; 1(2):109-23. PubMed ID: 9222988 [Abstract] [Full Text] [Related]
14. Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development. Wagner R, Deml L, Schirmbeck R, Reimann J, Wolf H. Behring Inst Mitt; 1994 Dec 20; (95):23-34. PubMed ID: 7755506 [Abstract] [Full Text] [Related]
15. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Deml L, Kratochwil G, Osterrieder N, Knüchel R, Wolf H, Wagner R. Virology; 1997 Aug 18; 235(1):10-25. PubMed ID: 9300033 [Abstract] [Full Text] [Related]
16. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Wagner R, Deml L, Fliessbach H, Wanner G, Wolf H. Virology; 1994 Apr 18; 200(1):162-75. PubMed ID: 7510434 [Abstract] [Full Text] [Related]
17. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses. Hewer R, Meyer D. Vaccine; 2005 Mar 18; 23(17-18):2164-7. PubMed ID: 15755588 [Abstract] [Full Text] [Related]
18. Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicity. Persson RH, Cao SX, Cates G, Yao FL, Klein MH, Rovinski B. Biologicals; 1998 Dec 18; 26(4):255-65. PubMed ID: 10403029 [Abstract] [Full Text] [Related]
20. Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses. Wagner R, Böltz T, Deml L, Modrow S, Wolf H. J Gen Virol; 1993 Jul 18; 74 ( Pt 7)():1261-9. PubMed ID: 7687647 [Abstract] [Full Text] [Related] Page: [Next] [New Search]